Background: This study determined the feasibility and potential efficacy of an evidence-based standardized smoking cessation intervention delivered by vascular surgeons to smokers with peripheral arterial disease.
Guidelines endorsed by the Centers for Disease Control and Prevention (CDC) and the United States Preventive
Task Force recommend that all health care providers provide smoking cessation counseling at each visit and patient encounter.
1 This is especially important for patients facing vascular interventions, such as angioplasty or surgical bypass, because smoking cessation has been shown to reduce the risk of major complications, improve bypass graft patency, and limit the risk of major limb amputation. 2, 3 Current guidelines recommend a three-component approach that incorporates physician advice, nicotine replacement therapy (NRT), and longitudinal counseling from a free, telephone-based quitline. 1, 4 However, successful implementation of evidencebased smoking cessation varies broadly, even for patients facing vascular surgery. For example, a study from the Vascular Study Group of New England demonstrated that smoking cessation in the year after vascular procedures varies nearly threefold, from 28% to 62%. 5 Further, fewer than one in five patients with peripheral arterial disease (PAD) receives evidence-based help with quitting smoking near the time of invasive procedures. 6, 7 Surgeons who do not provide smoking cessation often cite time constraints, lack of familiarity with resources for smoking cessation, a perception that smoking cessation is the responsibility of primary care providers, and overall discomfort with smoking cessation counseling as to providing recommended care. 8 The fact that surgeons are less likely to counsel patients on smoking cessation than primary care or medical providers represents a significant lost opportunity to provide cessation at a key "teachable moment." 6, 9 We hypothesized that implementation of a brief, evidence-based smoking cessation intervention would be feasible for patients facing invasive treatments for PAD. This report describes a pilot, multicenter, clusterrandomized trial called the Vascular Physician Offer and Report (VAPOR) trial in which a standardized, brief smoking cessation intervention was compared with usual care for patients with PAD. Eight vascular surgery practices were randomized to provide usual care for smoking cessation or a standardized protocol consisting of (1) physician "very brief advice" to stop smoking, (2) offering NRT, and (3) referral to a phone-based counseling service.
METHODS
Overview. The Institutional Review Boards at all sites approved the trial. To assess the feasibility and pilot efficacy of a surgeon-delivered, brief smoking cessation intervention, we conducted a multicenter, pilot, clusterrandomized clinical trial that compared the "Offer and Report" protocol to the usual care provided by vascular surgeons in everyday practice. The Offer and Report protocol is an adaption of the CDC's recommendations for smoking cessation, designed using physician "very brief advice" designed by the National Centre for Smoking Cessation and Training for use in England's National Health Service. [10] [11] [12] Our primary outcome measure was smoking cessation at 3 months after the intervention.
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Study intervention. The development and testing of our intervention has been described in earlier work. 16, 17 The intervention consisted of (1) physician-delivered "very brief advice" about smoking cessation, 12, 18, 19 (2) provision of a prescription for NRT to assist in smoking cessation, 20 and (3) active referral to telephone-based smoking cessation counseling by contacting a state-level quitline for patients using a fax-based referral system. We generated preprinted pocket cards ( Supplementary Fig 1, online only) to help study physicians remember each of the three steps and the dosages of commonly used NRT medications. We supplied each practice with copies of their state-level quitline fax referral form. Training for this intervention was administered to all intervention sites using two 2-hour-long Web-based seminars for study site leaders using a study protocol. We reviewed this protocol with site-specific study coordinators at the inception of the study and additionally during biweekly 1-hour-long teleconference protocol review and implementation meetings. These meetings took place for all site coordinators for the entire study period. 17 Finally, surgeons at each site participated in two additional interim Web-based conference calls to review protocol implementation.
Outcome assessment. Patients were screened for study enrollment before their clinic visit, and consent was obtained by study nurses before the clinic visit if patients were willing to participate. Study nurses recorded whether each of the three components of the intervention was administered by accompanying the patient throughout the study visit, including during the patient's interaction with the vascular surgeon. Patients in both arms then completed Patient Reported Outcomes Measurement Information System (PROMIS) Smoking Item Bank Surveys (RAND Corporation, Santa Monica, Calif), which included questions regarding smoking history, quit interest, and assessment of nicotine dependence and smoking-related harms. 15 No financial incentive was provided. Biochemical analysis to assess tobacco use was not performed. Study nurses also assessed 3-month outcomes using standardized instruments, which included assessment of tobacco use over the last 7 days, as the PROMIS Smoking Item Bank surveys related to Health Expectancies and Nicotine Addiction 15 ( Supplementary Fig 2, Recommendation:
The authors suggest that a larger trial be conducted to determine the efficacy of brief, surgeon-delivered smoking cessation intervention.
visits were not available. For patients in whom follow-up was missing, systematic attempts to contact patients by phone, letter, office visit, primary care physician contact, or family reference contact were performed. Demographics, patient, and practice characteristics were also collected.
Randomization, enrollment goals, and analysis. Randomization of eight clinical sites occurred in a 1:1 ratio for the intervention or the control protocol. All sites were staffed by vascular surgeons. The eight sites consisted of seven academic practices and one large community-based practice. Before the study was implemented, we estimated the effect size expected from our intervention. Preliminary estimates suggested that 15% to 30% of patients enrolled in smoking cessation programs supplemented by NRT achieve durable smoking cessation at 1 year. 6, 21 Further, recent work suggested that patients are more than twice as likely to quit smoking near the time of a vascular surgery procedure compared with patients not treated with invasive procedures. 5 Our enrollment goal was 25 patients per practice. We estimated that at this study size, our pilot would have 60% power to detect a 30% relative difference (absolute difference, 25% and 17%) in cessation rates between two independent clusters of practices. Given this limited power, the trial was designed to demonstrate the feasibility of implementing the intervention and allow refinement of the potential effect size associated with the intervention for future trials.
In measuring our primary outcome, we calculated crude 3-month smoking cessation rates by site and compared rates between our intervention and control groups. Intraclass correlation coefficients were used to adjust for clustering within sites. 22 This adjustment accounted for within-site clustering of patient characteristics at each of the eight sites in our trial. If patients underwent surgical or endovascular procedures collected within the Vascular Quality Initiative's data registry, information about these procedures was also recorded, and the data were linked to our study files to create a data set that contained smoking data as well as demographic and procedural data, when available. Finally, to ascertain the effects of factors other than our study intervention associated with smoking cessation, we generated logistic models to determine factors that were independently associated with successful smoking cessation at 3 months. These models used smoking cessation as the outcome measure and then used patient demographics, Smoking Item Bank responses, and surgical characteristics to determine factors associated with smoking cessation.
RESULTS
Enrollment and characteristics of the sample. Across the eight vascular surgery practices, we enrolled 156 patients between September 1, 2014, and July 31, 2015. Overall, 65 patients were enrolled in the four intervention practices, and 91 patients were enrolled in the four control practices. Patients in the intervention and control practices were similar in demographics and smoking-related domains (Table I) . Patients were predominantly male (65% intervention group, 77% control group; P ¼ .14), with an average age of 61 years. Patients had similar PROMIS health expectancy and nicotine dependence scores in the intervention and control practices at the time of the intervention. Patients smoked w14 cigarettes per day in both groups (14.9 intervention, 14.2 control; P ¼ .644); 78% of intervention patients and 77% of control patients had previously quit (P ¼ .861). Although patients in both groups were long-term smokers, those in the intervention group smoked fewer pack-years (37.4 pack-years) than those in the control group (41.7 pack-years; P ¼ .02). Overall, 30% (42 of 156) of patients underwent a vascular procedure after the intervention according to data entered in the Vascular Quality Initiative registry.
Intervention delivery, by study arm. Each of the three individual components of the smoking cessation intervention was significantly more likely to be provided to patients in the intervention group than in the control group (Table I) ; for example, 98% of patients in the intervention group and 77% in the control group received smoking cessation advice (P < .001). Differences between the intervention and control groups were larger, however, for the other two components of the smoking cessation intervention: NRT was offered in 76% vs 16% (P < .001), and quitline referral was made in 98% vs 33%, respectively (P < .0001). Overall, receipt of all three components was confirmed by 75% of patients in the intervention practices but by only 7% of patients in the control practices (P < .001). Neither auditing of actual quitline phone discussions nor confirmation of filling of prescriptions for NRT was performed as part of this trial.
Smoking cessation at 3-month follow-up, by intervention and control groups. Our main outcome measure was assessed in 90.4% of the cohort at 3 months after the intervention. Of the 156 patients, 15 (9.6% overall, 8 in the intervention practices, and 7 in the control practices) were lost to follow-up (Fig 1) . Three of the 141 remaining patients died before the 3-month follow-up (1 in the intervention group, 2 in the control group) and were analyzed as still smoking at the 3-month follow-up. This left 138 patients (56 in the intervention group, 82 in the control group) available for assessment of the outcome measure. Patients who died before completing follow-up were assumed to be smokers at the time of their death, in a conservative assumption.
Of the 138 patients whose smoking status was assessed at 3 months after the intervention, 49 had quit smoking (35.5% overall). At 3 months, 23 of 57 patients (40.3%) in the intervention group quit smoking (23 of 56 patients who completed follow-up, plus 1 death included in the analysis in the denominator as a smoker) and 26 of 84 patients (30.9%) In the control group who completed the follow-up quit smoking (including 2 deaths included in the denominator as smokers). Quit rates were higher in the intervention group (40.3%) than the control group (30.9%), but this difference did not reach statistical significance (unadjusted P ¼ .250; Fig 2) . In models adjusting for our cluster randomized design, the odds ratio (OR) for achieving smoking cessation in the intervention group was 1.51 (95% confidence interval [CI], 0.58-3.91; adjusted P ¼ .470).
Factors associated with smoking cessation and power calculations for larger trial. Results of the multivariable logistic regression model predicting smoking cessation are summarized in Table II . With respect to the specific intervention components (physician advice, NRT prescription, and telephone counseling) participation in a phone-based quitline had the smallest magnitude of association with smoking cessation, whereas physician advice and NRT were associated with a higher likelihood of achieving smoking cessation. Use of a quitline was not associated with smoking cessation. Model results also show that certain health expectancy and nicotine dependence questions were associated with smoking cessation. For example, those patients who reported worrying that cigarettes "were taking years off my life" were threefold more likely to quit. Conversely, those patients who "often" or "always" described "reaching for cigarettes when waking up" were 83% less likely to achieve smoking cessation. Overall, this model had good discrimination (receiver operating characteristic curve ¼ .77) and a goodnesseof-fit statistic demonstrating good fit with the actual data seen in the study sample (goodness-of-fit statistic P ¼ .342).
Based on the observed effect size of the smoking cessation intervention (OR, 1.51; 95% CI, 0.58-3.91), we examined the sample sizes necessary to conduct a fully powered randomized trial. We determined that to achieve statistical significance in a full-size randomized trial, we would need to enroll >600 patients in each arm (intervention vs control), with site (or cluster) randomization adding to this sample size depending on the number and size of the sites. For example, if a cluster-randomized trial with 20 sites was performed, 34 patients per cluster would be required, resulting in a total sample size of 680 patients per treatment arm, assuming an intracluster correlation of 0.01.
DISCUSSION
This trial of a brief smoking cessation intervention designed for vascular surgeons treating patients facing decisions about invasive treatments demonstrated the feasibility of our intervention. Across eight vascular surgery practices, we found it was feasible and successful to deliver a systematic, evidence-based smoking cessation intervention. In the intervention practices, 75% of patients received all three components of the intervention compared with 7% in the control practices. And although we found that patients in the intervention group were more likely to achieve smoking cessation, with the limited size of our pilot trial, this finding was not statistically significant. Delivering evidence-based smoking cessation interventions to patients facing procedural-based subspecialty care has been shown to be a potentially effective treatment paradigm. In several data syntheses compiled in Cochrane Database of Systematic Reviews 10,23-26 (Table III) , delivering smoking cessation interventions at a time when the patient is most likely to "hear" smoking cessation advicedthe "teachable moment"dhas been attempted near the time of cardiac catheterization for coronary artery disease, treatment for lung cancer, and other types of health care interventions. 16, 27, 28 Smoking cessation interventions at this key time in a patient's health care have been shown to potentially improve smoking cessation rates by 40%. 10, 28 The manner in which smoking cessation interventions are delivered may matter just as much as the timing, especially for patients facing invasive treatments. In a study of primary care practices, delivering smoking cessation advice using a standardized empathetic, patient-centered approach increased patients' readiness to quit from 65% to 84%. 9, 27 This may represent another avenue to maximize the potential effect of a smoking cessation interventiond delivering it at the right time, in the best way, to patients who are listening when their surgeon is discussing an invasive treatment. 16 Potential advantages aside, the goal of this study was to demonstrate feasibility and establish a range of efficacy measures for the planning of a larger, clusterrandomized trial. We identified several successes and challenges during this effort. Despite initial concerns expressed by our surgeons about adhering to an evidence-based smoking cessation protocol, we found that the surgeons at the intervention sites were able to deliver the smoking cessation intervention successfully, including the quitline referral and medication components, with little disruption of their clinical workflow and without substantive changes in existing clinical support staff. We also learned of the difficulties in performing smoking cessation interventions in populations that include smokers who are not necessarily ready to quit smoking. In our study, nearly 30% reported having no motivation to quit, and many of these patients were difficult to reach in follow-up. For example, 18% of patients who did not quit smoking at 3 months also refused to complete our follow-up survey of smoking health expectancies and nicotine dependence. An additional 10% of patients were unable to be contacted for 3-month follow-up. These challenges suggest that incentives, such as financial payments, will be needed to ensure optimal follow-up, especially among patients not motivated to quit. Our findings have several implications. First, we integrated an evidence-based smoking cessation program into everyday clinical practice in vascular surgery clinics across the United States. This integration argues that evidence-based smoking cessation should be considered an achievable goal for routine vascular surgery practice.
Second, our results suggest that the most important parts of smoking cessation interventions for patients facing vascular procedures include input from their surgeon and support for addiction using nicotine replacement; therefore, facilitating the delivery of these components in future studies will be a key priority in future, larger trials.
Finally, our smoking cessation rates, in both the intervention and control arms, are slightly higher than smoking cessation rates obtained in patients not facing surgery, suggesting the potential opportune time for perioperative smoking cessation.
Our study also has several limitations. First, in planning for this trial, we planned to have a 20% to 30% effect size, based on prior studies of smoking cessation interventions for patients facing surgical treatments. 17 Our limited funding necessitated this trial to collect preliminary information, and efforts are underway to secure funding for a larger, definitive study. Second, our study did not measure expired carbon monoxide or use cotinine testing. Large crosssectional studies have shown these tests may detect smokers who will report cessation even though they are actively smoking tobacco. [29] [30] [31] However, these tests are limited by false-positive results that can be equal in incidence to the proportion of smokers who will falsely report cessation, especially if the patients reside with other smokers such as their spouse or family members. Third, although CDC guidelines recommend quitline referral and provision of NRT, actually delivering these measures to patients presents logistic and financial challenges to certain patient populations. For example, the cost of varenicline, among the most effective medical therapies for smoking cessation, can be >$200 monthly. However, the Affordable Care Act, passed in 2010, aimed to enact specific support for smoking cessation during 2013 and 2015 in several states, and future health policy will likely argue to make these supports more broadly available. 32 Fourth, despite linking our data to procedures as collected in the Vascular Quality Initiative, we found little interaction with procedure type and quit rates. Of those patients who underwent procedures after the trial, most were carotid endarterectomies (38%), followed by endovascular aneurysm repair (21%) and a variety of lower extremity vascular procedures (w10%). Larger samples in our future work may find associations where our pilot effort was not powered to detect these differences.
Finally, we also learned about the importance of recognizing the different individual characteristics of each practice site. For example, we learned that a practice in the control group had a systematic smoking cessation program in a perioperative clinic outside of the vascular surgery office that closely paralleled the treatments in our intervention arm. This practice had referral requirements in their health center that mandated institution of evidence-based smoking cessation. In other words, even though surgeons at this site behaved like "control" group surgeons, systematic policies across their institution effectively delivered most components of the evidence-based intervention. When we performed an analysis that removed this site from the control group, our findings were nearly significant, even when adjusting for our cluster-randomized study design (smoking cessation rate 40% vs 24%; OR, 2.12; 95% CI, 0.93-4.83; P ¼ .06). However, given that this site was randomized to the control arm, we reported it as such in our intention-to-treat analysis.
CONCLUSIONS
Our pilot study of an evidence-based smoking cessation intervention demonstrated that a brief, standardized, smoking cessation intervention is feasible and can be delivered effectively by vascular surgeons. The most important aspects of this intervention appear to be the advice from the surgeon as well as encouraging the patient facing surgical treatment to use NRT as a tool to help him or her quit smoking. A larger trial testing the implementation of this evidence-based smoking cessation intervention for patients being treated by vascular surgeons is warranted and may help improve the delivery of perioperative smoking cessation for patients with PAD.
